Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy.

Anil Parsram Bidkar Sinan Wang Kondapa Naidu Bobba Emily Chan Scott Bidlingmaier Emily A Egusa Robin Peter Umama Ali Niranjan Meher Anju Wadhwa Suchi Dhrona Chandrashekhar Dasari Denis R Beckford-Vera Yang Su Ryan Tang Li Zhang Jiang He David M Wilson Rahul R Aggarwal Henry F VanBrocklin Youngho Seo Jonathan Chou Bin Liu Robert Richard Flavell

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

[225Ac]DOTA-YS5 suppressed the growth of cell-derived and patient-derived xenografts, including PSMA-positive and deficient models. Overall, this preclinical study confirms that [225Ac]DOTA-YS5 is a highly effective treatment and suggests feasibility for clinical translation of CD46 targeted radioligand therapy in PCa.

Keyphrases

prostate cancer
pet ct
pet imaging
cancer therapy
stem cells
cell therapy